Target Name: MIR1291
NCBI ID: G100302221
Review Report on MIR1291 Target / Biomarker Content of Review Report on MIR1291 Target / Biomarker
MIR1291
Other Name(s): hsa-miR-1291 | mir-1291 | hsa-mir-1291 | MIRN1291 | MicroRNA 1291 | Hsa-mir-1291 | microRNA 1291

MIR1291: A Drug Target / Disease Biomarker

MIR1291, also known as interleukin-12 (IL-12), is a protein that is expressed in various tissues throughout the body, including the immune system, skin, and nervous system. It is a cytokine that plays a crucial role in the regulation of inflammation and immune responses. MIR1291 has been identified as a potential drug target and is currently being studied for its potential therapeutic uses.

MIR1291 is a member of the IL-12 family, which includes several other cytokines that play important roles in the immune system. IL-12 is a cytokine that is involved in the regulation of inflammation, immune tolerance, and tissue repair. It is produced by various types of immune cells, including T cells, B cells, and natural killer cells. MIR1291 is similar to other members of the IL-12 family in that it is characterized by the presence of a signal-to-noise ratio (SNR) domain and a cytoplasmic tail.

MIR1291 has been shown to play a role in the regulation of inflammation and immune responses. It is produced by various immune cells in response to the presence of foreign particles, such as bacteria, viruses, or cancer cells. MIR1291 has been shown to induce the production of other cytokines, such as IL-10 and IL-13, which are important for the regulation of inflammation and immune responses. It has also been shown to regulate the activity of immune cells, such as T cells and B cells, and to play a role in the regulation of tissue repair.

MIR1291 has been identified as a potential drug target due to its ability to regulate the immune system and to induce the production of other cytokines. It is also a good candidate for a drug because it is relatively simple to produce and because it does not have a lot of known side effects. MIR1291 has also been shown to be effective in animal models of several diseases, including cancer, autoimmune diseases, and respiratory infections.

In addition to its potential therapeutic uses, MIR1291 has also been shown to have potential as a biomarker. It has been shown to be elevated in the blood and lymphatic fluid of patients with several types of cancer, including breast cancer, lung cancer, and colon cancer. It has also been shown to be elevated in the blood and lymphatic fluid of patients with autoimmune diseases, such as rheumatoid arthritis and lupus. These findings suggest that MIR1291 may be a useful biomarker for the diagnosis and monitoring of certain types of cancer and autoimmune diseases.

MIR1291 is also a good candidate for a potential diagnostic diagnostic tool. Its presence in the blood and lymphatic fluid of cancer and autoimmune diseases can be detected using techniques such as flow cytometry, which is a type of immunofluorescence. MIR1291 can also be detected in other types of cells, such as T cells and B cells, using techniques such as immunofluorescence or enzyme-based assays. These findings suggest that MIR1291 may be a useful diagnostic tool for the detection of cancer and autoimmune diseases.

In conclusion, MIR1291 is a protein that is expressed in various tissues throughout the body and is involved in the regulation of inflammation and immune responses. It has been shown to be a potential drug target and to have potential as a biomarker and diagnostic tool. Further research is needed to fully understand the role of MIR1291 in the immune system and to determine its potential therapeutic uses.

Protein Name: MicroRNA 1291

The "MIR1291 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1291 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1292 | MIR1293 | MIR1294 | MIR1295A | MIR1295B | MIR1296 | MIR1297 | MIR1298 | MIR1299 | MIR1301 | MIR1302-1 | MIR1302-10 | MIR1302-11 | MIR1302-2 | MIR1302-3 | MIR1302-4 | MIR1302-5 | MIR1302-6 | MIR1302-7 | MIR1302-8 | MIR1302-9 | MIR1303 | MIR1304 | MIR1305 | MIR1306 | MIR1307 | MIR130A | MIR130B | MIR132 | MIR1321 | MIR1322 | MIR1323 | MIR1324 | MIR133A1 | MIR133A1HG | MIR133A2 | MIR133B | MIR134 | MIR1343 | MIR135A1 | MIR135A2 | MIR135B | MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139 | MIR140 | MIR141 | MIR142 | MIR143 | MIR144 | MIR145 | MIR1468 | MIR1469 | MIR146A | MIR146B | MIR1470 | MIR1471 | MIR147A | MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1 | MIR153-2 | MIR1537 | MIR1538 | MIR1539 | MIR154 | MIR155 | MIR155HG | MIR1587 | MIR15A | MIR15B | MIR16-1 | MIR16-2 | MIR17 | MIR17HG | MIR181A1 | MIR181A1HG | MIR181A2 | MIR181A2HG | MIR181B1 | MIR181B2 | MIR181C | MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187